| Literature DB >> 25681338 |
Motoyasu Onishi1, Koji Ozasa2, Kouji Kobiyama3, Keiichi Ohata3, Mitsutaka Kitano4, Keiichi Taniguchi4, Tomoyuki Homma4, Masanori Kobayashi4, Akihiko Sato4, Yuko Katakai5, Yasuhiro Yasutomi6, Edward Wijaya7, Yoshinobu Igarashi8, Noriyuki Nakatsu8, Wataru Ise9, Takeshi Inoue9, Hiroshi Yamada8, Alexis Vandenbon7, Daron M Standley7, Tomohiro Kurosaki10, Cevayir Coban11, Taiki Aoshi3, Etsushi Kuroda3, Ken J Ishii12.
Abstract
Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. Their efficacies and mechanisms as drug-delivery systems have been investigated for decades, but their immunological properties have not been examined. In this study, we reprofiled hydroxypropyl-β-cyclodextrin (HP-β-CD) as a vaccine adjuvant and found that it acts as a potent and unique adjuvant. HP-β-CD triggered the innate immune response at the injection site, was trapped by MARCO(+) macrophages, increased Ag uptake by dendritic cells, and facilitated the generation of T follicular helper cells in the draining lymph nodes. It significantly enhanced Ag-specific Th2 and IgG Ab responses as potently as did the conventional adjuvant, aluminum salt (alum), whereas its ability to induce Ag-specific IgE was less than that of alum. At the injection site, HP-β-CD induced the temporary release of host dsDNA, a damage-associated molecular pattern. DNase-treated mice, MyD88-deficient mice, and TBK1-deficient mice showed significantly reduced Ab responses after immunization with this adjuvant. Finally, we demonstrated that HP-β-CD-adjuvanted influenza hemagglutinin split vaccine protected against a lethal challenge with a clinically isolated pandemic H1N1 influenza virus, and the adjuvant effect of HP-β-CD was demonstrated in cynomolgus macaques. Our results suggest that HP-β-CD acts as a potent MyD88- and TBK1-dependent T follicular helper cell adjuvant and is readily applicable to various vaccines.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25681338 PMCID: PMC4470223 DOI: 10.4049/jimmunol.1402027
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422